Global Neuroendocrine Tumor Treatment Market Size, Status and Forecast 2019-2025

Table of Contents

1 Report Overview

• 1.1 Study Scope
• 1.2 Key Market Segments
• 1.3 Players Covered
• 1.4 Market Analysis by Type
  • 1.4.1 Global Neuroendocrine Tumor Treatment Market Size Growth Rate by Type (2014-2025)
  • 1.4.2 Everolimus
  • 1.4.3 Sunitinib
  • 1.4.4 Lu-Dotatate
  • 1.4.5 Lanreotide
  • 1.4.6 Octreotide
• 1.5 Market by Application
  • 1.5.1 Global Neuroendocrine Tumor Treatment Market Share by Application (2019-2025)
  • 1.5.2 Hospitals
  • 1.5.3 Clinic
  • 1.5.4 Others
• 1.6 Study Objectives
• 1.7 Years Considered

2 Global Growth Trends

• 2.1 Neuroendocrine Tumor Treatment Market Size
• 2.2 Neuroendocrine Tumor Treatment Growth Trends by Regions
  • 2.2.1 Neuroendocrine Tumor Treatment Market Size by Regions (2019-2025)
  • 2.2.2 Neuroendocrine Tumor Treatment Market Share by Regions (2014-2019)
• 2.3 Industry Trends
  • 2.3.1 Market Top Trends
  • 2.3.2 Market Drivers
  • 2.3.3 Market Challenges
  • 2.3.4 Porter’s Five Forces Analysis

3 Market Share by Key Players

• 3.1 Neuroendocrine Tumor Treatment Market Size by by Players
  • 3.1.1 Global Neuroendocrine Tumor Treatment Revenue by by Players (2014-2019)
  • 3.1.2 Global Neuroendocrine Tumor Treatment Revenue Market Share by by Players (2014-2019)
  • 3.1.3 Global Neuroendocrine Tumor Treatment Market Concentration Ratio (CR5 and HHI)
• 3.2 Neuroendocrine Tumor Treatment Key Players Head office and Area Served
• 3.3 Key Players Neuroendocrine Tumor Treatment Product/Solution/Service
• 3.4 Date of Enter into Neuroendocrine Tumor Treatment Market
• 3.5 Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type and Application

• 4.1 Global Neuroendocrine Tumor Treatment Market Size by Type (2014-2019)
• 4.2 Global Neuroendocrine Tumor Treatment Market Size by Application (2014-2019)

5 North America

• 5.1 North America Neuroendocrine Tumor Treatment Market Size (2014-2019)
• 5.2 Neuroendocrine Tumor Treatment Key Players in North America
• 5.3 North America Neuroendocrine Tumor Treatment Market Size by Type
• 5.4 North America Neuroendocrine Tumor Treatment Market Size by Application

6 Europe

• 6.1 Europe Neuroendocrine Tumor Treatment Market Size (2014-2019)
• 6.2 Neuroendocrine Tumor Treatment Key Players in Europe
• 6.3 Europe Neuroendocrine Tumor Treatment Market Size by Type
• 6.4 Europe Neuroendocrine Tumor Treatment Market Size by Application

7 China

• 7.1 China Neuroendocrine Tumor Treatment Market Size (2014-2019)
• 7.2 Neuroendocrine Tumor Treatment Key Players in China
• 7.3 China Neuroendocrine Tumor Treatment Market Size by Type
• 7.4 China Neuroendocrine Tumor Treatment Market Size by Application

8 Japan

• 8.1 Japan Neuroendocrine Tumor Treatment Market Size (2014-2019)
• 8.2 Neuroendocrine Tumor Treatment Key Players in Japan
• 8.3 Japan Neuroendocrine Tumor Treatment Market Size by Type
• 8.4 Japan Neuroendocrine Tumor Treatment Market Size by Application

9 Southeast Asia

• 9.1 Southeast Asia Neuroendocrine Tumor Treatment Market Size (2014-2019)
• 9.2 Neuroendocrine Tumor Treatment Key Players in Southeast Asia
• 9.3 Southeast Asia Neuroendocrine Tumor Treatment Market Size by Type
• 9.4 Southeast Asia Neuroendocrine Tumor Treatment Market Size by Application

10 India

• 10.1 India Neuroendocrine Tumor Treatment Market Size (2014-2019)
• 10.2 Neuroendocrine Tumor Treatment Key Players in India
• 10.3 India Neuroendocrine Tumor Treatment Market Size by Type
• 10.4 India Neuroendocrine Tumor Treatment Market Size by Application

11 Central & South America

• 11.1 Central & South America Neuroendocrine Tumor Treatment Market Size (2014-2019)
• 11.2 Neuroendocrine Tumor Treatment Key Players in Central & South America
• 11.3 Central & South America Neuroendocrine Tumor Treatment Market Size by Type
• 11.4 Central & South America Neuroendocrine Tumor Treatment Market Size by Application

12 International Players Profiles

• 12.1 Exelixis, Inc.
  • 12.1.1 Exelixis, Inc. Company Details
  • 12.1.2 Company Description and Business Overview
  • 12.1.3 Neuroendocrine Tumor Treatment Introduction
  • 12.1.4 Exelixis, Inc. Revenue in Neuroendocrine Tumor Treatment Business (2014-2019))
  • 12.1.5 Exelixis, Inc. Recent Development
• 12.2 Advanced Accelerator Applications
  • 12.2.1 Advanced Accelerator Applications Company Details
  • 12.2.2 Company Description and Business Overview
  • 12.2.3 Neuroendocrine Tumor Treatment Introduction
  • 12.2.4 Advanced Accelerator Applications Revenue in Neuroendocrine Tumor Treatment Business (2014-2019)
  • 12.2.5 Advanced Accelerator Applications Recent Development
• 12.3 Dauntless Pharmaceuticals, Inc.
  • 12.3.1 Dauntless Pharmaceuticals, Inc. Company Details
  • 12.3.2 Company Description and Business Overview
  • 12.3.3 Neuroendocrine Tumor Treatment Introduction
  • 12.3.4 Dauntless Pharmaceuticals, Inc. Revenue in Neuroendocrine Tumor Treatment Business (2014-2019)
  • 12.3.5 Dauntless Pharmaceuticals, Inc. Recent Development
• 12.4 Hutchinson Medipharma Limited
  • 12.4.1 Hutchinson Medipharma Limited Company Details
  • 12.4.2 Company Description and Business Overview
  • 12.4.3 Neuroendocrine Tumor Treatment Introduction
  • 12.4.4 Hutchinson Medipharma Limited Revenue in Neuroendocrine Tumor Treatment Business (2014-2019)
  • 12.4.5 Hutchinson Medipharma Limited Recent Development
• 12.5 Ispen
  • 12.5.1 Ispen Company Details
  • 12.5.2 Company Description and Business Overview
  • 12.5.3 Neuroendocrine Tumor Treatment Introduction
  • 12.5.4 Ispen Revenue in Neuroendocrine Tumor Treatment Business (2014-2019)
  • 12.5.5 Ispen Recent Development
• 12.6 Novartis AG
  • 12.6.1 Novartis AG Company Details
  • 12.6.2 Company Description and Business Overview
  • 12.6.3 Neuroendocrine Tumor Treatment Introduction
  • 12.6.4 Novartis AG Revenue in Neuroendocrine Tumor Treatment Business (2014-2019)
  • 12.6.5 Novartis AG Recent Development
• 12.7 Progenics Pharmaceuticals, Inc.
  • 12.7.1 Progenics Pharmaceuticals, Inc. Company Details
  • 12.7.2 Company Description and Business Overview
  • 12.7.3 Neuroendocrine Tumor Treatment Introduction
  • 12.7.4 Progenics Pharmaceuticals, Inc. Revenue in Neuroendocrine Tumor Treatment Business (2014-2019)
  • 12.7.5 Progenics Pharmaceuticals, Inc. Recent Development
• 12.8 Tarveda Therapeutics
  • 12.8.1 Tarveda Therapeutics Company Details
  • 12.8.2 Company Description and Business Overview
  • 12.8.3 Neuroendocrine Tumor Treatment Introduction
  • 12.8.4 Tarveda Therapeutics Revenue in Neuroendocrine Tumor Treatment Business (2014-2019)
  • 12.8.5 Tarveda Therapeutics Recent Development

13 Market Forecast 2019-2025

• 13.1 Market Size Forecast by Product (2019-2025)
• 13.2 Market Size Forecast by Application (2019-2025)
• 13.3 Market Size Forecast by Regions
• 13.4 North America
• 13.5 Europe
• 13.6 China
• 13.7 Japan
• 13.8 Southeast Asia
• 13.9 India
• 13.10 Central & South America

14 Analyst's Viewpoints/Conclusions

15 Appendix

• 15.1 Research Methodology
  • 15.1.1 Methodology/Research Approach
    • 15.1.1.1 Research Programs/Design
    • 15.1.1.2 Market Size Estimation
    • 15.1.1.3 Market Breakdown and Data Triangulation
  • 15.1.2 Data Source
    • 15.1.2.1 Secondary Sources
    • 15.1.2.2 Primary Sources
• 15.2 Disclaimer